|Rapid Review complete
|Treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Baricitinib may be used as monotherapy or in combination with methotrexate.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Evaluation Recommended at the Submitted Price
The HSE has approved reimbursement following confidential price negotiations November 2017